Microbiology and infectious disease testing represent one of the largest and most dynamic application segments in IVD. The shift from traditional culture-based microbiology to molecular-based syndromic testing is accelerating, driven by the need for faster time-to-result, broader pathogen coverage from a single sample, and stewardship of antimicrobial therapy. BioFire Diagnostics received FDA 510(k) clearance for its FilmArray Gastrointestinal Panel Mid in January 2025. The IVD industry is witnessing a decisive shift from single-pathogen to syndromic testing panels that simultaneously detect multiple pathogens linked to a specific clinical syndrome. Antimicrobial resistance diagnostics — identifying resistant organisms including MRSA, CRE, and VRE directly from clinical samples — is a rapidly growing sub-segment driven by global AMR stewardship programs. COVID-19 demonstrated the critical role of IVD in outbreak response at population scale, creating permanent investment in rapid molecular infrastructure.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Microbiology and Infectious Disease IVD Market Size and Forecast 2025-2030 by Segment
• Syndromic Testing Panels — Respiratory, Gastrointestinal, Meningitis, and Blood Culture
• Molecular Microbiology — PCR-Based Pathogen Detection and Multiplex Panels
• Blood Culture and Bacteremia — Automated Systems and Rapid ID/AST
• Antimicrobial Resistance Diagnostics — MRSA, CRE, VRE, and Rapid AST
• Parasitology and Mycology — Malaria, Fungal Infection, and Tropical Disease Testing
• Outbreak Response Platforms — Rapid Molecular Infrastructure and Surge Capacity
• Competitive Landscape — bioMérieux, Hologic, BD, Roche, BioFire, and Cepheid
• Investment and Partnership Opportunities
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Highest-priority opportunities
- Competitive landscape summary
- Strategic recommendations
2. Market Overview
- Market definition, scope and segmentation
- Key demand drivers and restraints
- Regulatory environment
3. Syndromic Testing Panels
- Respiratory panels — BioFire, Roche, Abbott, and Hologic
- Gastrointestinal and meningitis/encephalitis panels
- Blood culture identification panels
4. Molecular Microbiology
- PCR-based pathogen detection
- BD MAX, Panther, and GeneXpert platform competition
- Transition from culture to molecular methods
5. Blood Culture and Bacteremia
- Automated blood culture systems — BD and bioMérieux
- Rapid organism identification — MALDI-TOF and molecular
- Competitive dynamics and installed base analysis
6. Antimicrobial Resistance Diagnostics
- MRSA, CRE, and VRE screening
- Rapid antimicrobial susceptibility testing
- AMR stewardship programs and their market implications
7. Parasitology and Mycology
- Malaria rapid diagnostics — POC and molecular
- Fungal infection diagnostics — culture, antigen, and molecular
- Tropical disease testing in resource-limited settings
8. Outbreak Response
- Rapid molecular capacity deployment
- Platform scalability and reagent supply chain
- Post-COVID legacy infrastructure and its redirection
9. Competitive Landscape
- bioMérieux, BD, Roche, BioFire, Cepheid, and Hologic
- New entrants and molecular platform challengers
- M&A and partnership activity 2023-2025
10. Regional Market Analysis
- 10.1 North America (U.S., Canada, Mexico)
- 10.2 Europe (38 countries)
- 10.3 Asia-Pacific (18 countries)
- 10.4 Latin America (22 countries)
- 10.5 Middle East (11 countries)
- 10.6 Africa and Rest of World
11. Strategic Conclusions and Recommendations
- Highest-priority opportunities by segment and region
- Market entry and expansion strategies
- M&A, partnership and investment priorities
12. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. Syndromic Testing Panels — Application Landscape and Leading Suppliers 2025
Table 2. Molecular Microbiology — Platform Comparison and Leading Suppliers 2025
Table 3. Blood Culture Systems — Platform Comparison and Leading Suppliers 2025
Table 4. Antimicrobial Resistance Diagnostics — Application Landscape and Leading Suppliers 2025
Table 5. Parasitology and Mycology — Key Tests and Leading Suppliers 2025
Table 6. Outbreak Response Platforms — Capabilities and Leading Suppliers 2025
Table 7. Leading Suppliers and Competitive Positioning 2025
Table 8. M&A and Partnership Activity 2023-2025
Table 9. Regulatory Pathway Summary by Application 2025
Table 10. Key Risks and Mitigation Strategies
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
